X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (1434) 1434
life sciences & biomedicine (1383) 1383
humans (1319) 1319
memantine - therapeutic use (1175) 1175
memantine (1088) 1088
male (744) 744
alzheimer disease - drug therapy (638) 638
neurosciences & neurology (637) 637
female (570) 570
alzheimer's disease (557) 557
animals (551) 551
excitatory amino acid antagonists - therapeutic use (503) 503
aged (493) 493
neurosciences (483) 483
pharmacology & pharmacy (473) 473
cholinesterase inhibitors - therapeutic use (422) 422
psychiatry (405) 405
memantine - pharmacology (389) 389
clinical neurology (336) 336
receptors, n-methyl-d-aspartate - antagonists & inhibitors (324) 324
dementia (319) 319
treatment outcome (302) 302
middle aged (263) 263
rats (242) 242
aged, 80 and over (236) 236
drug therapy (227) 227
memantine - adverse effects (215) 215
excitatory amino acid antagonists - pharmacology (212) 212
dopamine agents - therapeutic use (205) 205
neurology (191) 191
dementia - drug therapy (188) 188
adult (186) 186
geriatrics & gerontology (185) 185
nootropic agents - therapeutic use (185) 185
memantine - administration & dosage (182) 182
methyl aspartate (174) 174
piperidines - therapeutic use (171) 171
indans - therapeutic use (169) 169
drug therapy, combination (167) 167
double-blind method (166) 166
glutamate (160) 160
alzheimers disease (156) 156
donepezil (147) 147
disease models, animal (146) 146
analysis (145) 145
nervous system agents (144) 144
mice (143) 143
clinical trials (142) 142
rivastigmine (141) 141
dose-response relationship, drug (140) 140
neuropsychological tests (134) 134
cholinesterase inhibitors (130) 130
medicine & public health (129) 129
alzheimer’s disease (124) 124
cognitive ability (123) 123
severity of illness index (123) 123
care and treatment (122) 122
neuroprotective agents - therapeutic use (119) 119
receptors, n-methyl-d-aspartate - metabolism (116) 116
research (116) 116
randomized controlled trials as topic (113) 113
glutamic acid receptors (112) 112
neurodegenerative diseases (112) 112
n-methyl-d-aspartic acid receptors (108) 108
cognition disorders - drug therapy (107) 107
activities of daily living (106) 106
alzheimer disease - psychology (106) 106
galantamine - therapeutic use (103) 103
pharmacology/toxicology (103) 103
rats, sprague-dawley (102) 102
cognition - drug effects (100) 100
alzheimer disease - diagnosis (98) 98
clinical trials as topic (98) 98
cognition (98) 98
internal medicine (97) 97
antiparkinson agents - therapeutic use (96) 96
time factors (96) 96
pharmacotherapy (95) 95
alzheimer disease - physiopathology (90) 90
drugs (89) 89
excitatory amino acid antagonists - adverse effects (88) 88
biomedicine (87) 87
antipsychotic agents - therapeutic use (86) 86
galantamine (86) 86
psychiatric status rating scales (85) 85
rodents (85) 85
brain (83) 83
memory (83) 83
general & internal medicine (82) 82
cholinesterase inhibitors - adverse effects (81) 81
mental disorders (81) 81
neuroprotection (81) 81
patients (81) 81
abridged index medicus (80) 80
medicine, general & internal (80) 80
brain - drug effects (79) 79
excitatory amino acid antagonists - administration & dosage (78) 78
pharmacology (78) 78
gerontology (77) 77
health aspects (77) 77
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1830) 1830
German (63) 63
Russian (30) 30
Spanish (22) 22
French (17) 17
Japanese (16) 16
Chinese (7) 7
Dutch (7) 7
Danish (4) 4
Portuguese (4) 4
Norwegian (3) 3
Polish (3) 3
Czech (1) 1
Finnish (1) 1
Hebrew (1) 1
Hungarian (1) 1
Italian (1) 1
Romanian (1) 1
Swedish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Book Review
2002, Volume 16, Issue 12, 14
The pathophysiology of Alzheimer's disease is complex and involves several different biochemical pathways. These include defective -amyloid (A) protein... 
FPF 1070, therapeutic use | Memantine, therapeutic use | Antidementias, therapeutic use | HMG CoA reductase inhibitors, therapeutic use | Antioxidants, therapeutic use | Neuroprotectants, therapeutic use | Chelating agents, therapeutic use | Nonsteroidal anti inflammatories, therapeutic use | Alzheimer's disease | Estrogens, therapeutic use | Ginkgo biloba leaf extract, therapeutic use | Pharmacotherapy | Neurology | Neurosciences | Medicine & Public Health | Psychiatry | Psychopharmacology | Pharmacology & Pharmacy | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Neuroprotective Agents - therapeutic use | Excitatory Amino Acid Antagonists - therapeutic use | Plant Extracts - pharmacology | Humans | Amino Acids - pharmacology | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Neuroprotective Agents - pharmacology | Alzheimer Disease - prevention & control | Immunotherapy | Phytotherapy | Chelating Agents - therapeutic use | Memantine - pharmacology | Alzheimer Disease - therapy | Clinical Trials as Topic | Excitatory Amino Acid Antagonists - pharmacology | Antioxidants - pharmacology | Chelating Agents - pharmacology | Amino Acids - therapeutic use | Ginkgo biloba | Antioxidants - therapeutic use | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Amyloid beta-Peptides - immunology | Memantine - therapeutic use | Plant Extracts - therapeutic use | Index Medicus
Book Review
Expert review of neurotherapeutics, ISSN 1473-7175, 02/2016, Volume 16, Issue 2, pp. 131 - 144
Adult Attention Deficit Hyperactivity Disorder (ADHD) is a prevalent psychiatric condition associated with high disability and frequent comorbidity. Current... 
Antidepressants | Attention Deficit Hyperactivity Disorder (ADHD) | Amphetamines | Efficacy | Lithium | Adults | Pharmacological Treatment | Metadoxine | Pharmacology & Pharmacy | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Humans | Paroxetine - therapeutic use | Venlafaxine Hydrochloride - therapeutic use | Dopamine Agents - therapeutic use | Droxidopa - therapeutic use | Pyrrolidonecarboxylic Acid - therapeutic use | Adrenergic alpha-Agonists - therapeutic use | Histamine Agents - therapeutic use | Central Nervous System Stimulants - therapeutic use | Desipramine - therapeutic use | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Pyridoxine - therapeutic use | Adult | Lobeline - therapeutic use | Benzhydryl Compounds - therapeutic use | Nomifensine - therapeutic use | Morpholines - therapeutic use | Bupropion - therapeutic use | Pyridines - therapeutic use | Wakefulness-Promoting Agents - therapeutic use | Duloxetine Hydrochloride - therapeutic use | Guanfacine - therapeutic use | Nicotinic Agonists - therapeutic use | Attention Deficit Disorder with Hyperactivity - drug therapy | Antidepressive Agents - therapeutic use | Mecamylamine - therapeutic use | Amphetamines - therapeutic use | Lithium Compounds - therapeutic use | Lisdexamfetamine Dimesylate - therapeutic use | Nicotinic Antagonists - therapeutic use | Quinazolinones - therapeutic use | Memantine - therapeutic use | Drug Combinations
Journal Article